Allevi Announces the Appointment of Taciana Pereira as CSO

Philadelphia, PA – Allevi Inc., a leader in the field of 3D bioprinting, announces that Taciana Pereira has been named as its Chief Scientific Officer. Taci has been at Allevi since 2017 and was previously the Vice President of Life Sciences, leading R&D, strategic partnerships, and product portfolio development. Originally from Curitiba, Brazil, she moved to the US to study bioengineering at Harvard University, where she was advised by Dr. David Mooney. She is currently the Chair of the 3D Bioprinting Committee for the Regenerative Medicine Manufacturing Society and the New Organ Alliance.

“We are thrilled to have Taci take on these additional responsibilities and are confident in her abilities to increase our presence in the drug discovery and biological implant markets. Taci already is involved in a number of studies with leading institutions including the previously announced COVID-19 drug screening project in collaboration with the Wistar Institute”, said Frank J. McCaney, CEO of Allevi.

Allevi is the developer of the world’s first desktop 3D bioprinter. It has devices in 40 countries around the world, including three bioprinter models, a portfolio of tissue-specific bioinks, and advanced software that automates the bioprinting workflow. Allevi is headquartered at the Pennovation Center in Philadelphia.   

For more information contact Madeline Winter at [email protected]